Bob Kramer, Emergent BioSolutions CEO (Emergent)
April 30, 2021 08:07 AM EDTUpdated 10:37 AM
Coronavirus
Manufacturing

Emer­gent reshuf­fles its man­u­fac­tur­ing brain trust as CEO sends mixed mes­sages around Covid-19 vac­cine de­ba­cle

Josh Sullivan

Weeks af­ter Mary­land-based Emer­gent BioSo­lu­tions bun­gled 15 mil­lion dos­es of J&J’s Covid-19 shot and was shut out of its own Bal­ti­more fa­cil­i­ty, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times